Anas Najjar
Overview
Explore the profile of Anas Najjar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
215
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Warasna B, Rajabi N, Mustafa B, Najjar A, Daraghmeh S, Maali A, et al.
Lancet
. 2021 Jul;
398 Suppl 1:S45.
PMID: 34227979
Background: Contraceptives have documented efficiency, but outcomes are highly dependent on women's understanding of how they should be used. We assessed the knowledge and attitudes of married Palestinian women about...
2.
Najjar A, Warasna B, Kitaneh I, Abu-Sharar S, Sawalha M, Jamous A, et al.
Lancet
. 2021 Jul;
398 Suppl 1:S40.
PMID: 34227974
Background: Older people (aged 60 years and older) are more susceptible than younger people to multiple medical disorders and are therefore more frequently exposed to polypharmacy. We investigated prevalence of...
3.
Najjar A, Najjar A, Karaman R
Molecules
. 2020 Feb;
25(4).
PMID: 32079289
Background: The design and development of prodrugs is the most common and effective strategy to overcome pharmacokinetic and pharmacodynamic drawbacks of active drugs. A respected number of prodrugs have been...
4.
Najjar A, Karaman R
Expert Opin Drug Discov
. 2019 Feb;
14(3):199-220.
PMID: 30714428
Ample efforts have been carried out to improve the efficacy of a variety of drugs. The prodrugs approach was found to be a safe haven for providing medications with improved...
5.
Najjar A, Karaman R
Expert Opin Drug Deliv
. 2018 Dec;
16(1):1-5.
PMID: 30558447
No abstract available.
6.
Zeiadeh I, Najjar A, Karaman R
Molecules
. 2018 May;
23(6).
PMID: 29843371
The blood brain barrier (BBB) is a dynamic and functional structure which poses a vast challenge in the development of drugs acting on the central nervous system (CNS). While most...
7.
Haddad F, Sawalha M, Khawaja Y, Najjar A, Karaman R
Molecules
. 2018 Jan;
23(1).
PMID: 29295587
: Parkinson's disease is an aggressive and progressive neurodegenerative disorder that depletes dopamine (DA) in the central nervous system. Dopamine replacement therapy, mainly through actual dopamine and its original prodrug...
8.
Sinokrot H, Smerat T, Najjar A, Karaman R
Molecules
. 2017 Oct;
22(10).
PMID: 29035325
: Poor pharmacokinetic profiles and resistance are the main two drawbacks from which currently used antiviral agents suffer, thus make them excellent targets for research, especially in the presence of...
9.
Najjar A, Rajabi N, Karaman R
Curr Pharm Des
. 2017 Feb;
23(16):2366-2376.
PMID: 28155621
Background: Intensive efforts have been implemented to improve the efficacy of platinum complexes especially with emerging cisplatin resistance and elevated cancer deaths. Platinum(IV) agents show better pharmacokinetics and decreased side...
10.
Najjar A, Amro Y, Kitaneh I, Abu-Sharar S, Sawalha M, Jamous A, et al.
PLoS One
. 2015 Jun;
10(6):e0129240.
PMID: 26046771
Background: Adequate patient knowledge about medications is essential for appropriate drug taking behavior and patient adherence. This study aims to assess and quantify the level of knowledge and adherence to...